var data={"title":"Polymyxin B: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polymyxin B: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6802?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">see &quot;Polymyxin B: Drug information&quot;</a> and <a href=\"topic.htm?path=polymyxin-b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polymyxin B: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709216\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When this drug is given IM, IV, or intrathecally, it should be given only to hospitalized patients, so as to provide constant supervision by a physician.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal function should be carefully determined, and patients with renal damage and nitrogen retention should have reduced dosage. Patients with nephrotoxicity due to polymyxin B sulfate usually show albuminuria, cellular casts, and azotemia. Diminishing urine output and a rising blood urea nitrogen (BUN) are indications for discontinuing therapy with this drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxic reactions may be manifested by irritability, weakness, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurring of vision. These are usually associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent or sequential use of other neurotoxic or nephrotoxic drugs with polymyxin B sulfate, particularly bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, and colistin should be avoided.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuromuscular blockade:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The neurotoxicity of polymyxin B sulfate can result in respiratory paralysis from neuromuscular blockade, especially when the drug is given soon after anesthesia or muscle relaxants.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Use in pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The safety of this drug in human pregnancy has not been established.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049460\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Ophthalmic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Urinary Irrigation</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25747919\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Due to toxicity risks, systemic use of polymyxin B should be limited to life-threatening multidrug resistant infection where less toxic alternatives are not effective or not tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe, life-threatening, multidrug resistant infection (excluding meningitis): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 25,000 to 40,000 units/kg/day divided every 6 hours; in premature neonates or newborns, doses as high as 45,000 units/kg/day have been used for <i>Pseudomonas aeruginosa</i> sepsis with limited clinical experience; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 15,000 to 40,000 units/kg/day divided every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049454\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">see &quot;Polymyxin B: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Due to increased toxicity risks, the systemic use of polymyxin B should be limited to life-threatening, multidrug resistant infection where less toxic alternatives are not effective or not tolerated. Multiple routes of administration available for use (eg, IV, IM, intrathecal, ophthalmic) and dosing is different based upon route; use extra precaution to verify dose and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing may be presented as units or mg; 10,000 units = 1 mg, use extra caution with prescribing and/or dispensing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe, life-threatening, multidrug resistant infection (excluding meningitis): </b>\n      <b>Note:</b> From experience in adult patients, safety data for single doses &gt;30,000 units/kg/dose or total daily doses &gt;2,000,000 units<b>/day </b>are extremely limited (Kassamali 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 25,000 to 40,000 units/kg/day divided every 4 to 6 hours; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 15,000 to 40,000 units/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 25,000 to 30,000 units/kg/day divided every 4 to 6 hours; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 15,000 to 25,000 units/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: Children &ge;2 years and Adolescents: Very limited data available: Dosing based on previous recommendations (Hoeprich 1970) and extrapolations from adult pharmacokinetic modeling (Sandri 2013) which assumes that dosing for pediatric patients &ge;2 years and adults is the same (per current manufacturer's labeling); some centers have used the following:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: 25,000 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: 25,000 to 30,000 units/kg/day divided every 12 hours; consider higher doses for organisms with higher MIC</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis; <i>Pseudomonas aeruginosa</i> or <i>Haemophilus influenzae:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Intrathecal: 20,000 units once daily for 3 to 4 days <b>or</b> 25,000 units once every other day; continue 25,000 units once every other day for at least 2 weeks after cultures of the CSF are negative</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years and Adolescents: Intrathecal: 50,000 units daily for 3 to 4 days, then every other day for at least 2 weeks after cultures of CSF are negative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection (VP-shunt infection, ventriculitis):</b> Limited data available: Children and Adolescents: Intraventricular/intrathecal: 20,000 to 50,000 units/day; lower doses should be used in smaller patients (Hoeprich 1970; Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ocular infection; <i>Pseudomonas aeruginosa:</i></b> Infants, Children, and Adolescents: Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: 0.1% to 0.25% solution (prepared from parenteral injection): 1 to 3 drops every hour, then increasing the interval as response indicates</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Subconjunctival injection: Up to 100,000 units/day not to exceed 25,000 units/<b>kg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Combined total therapy (systemic and ophthalmic instillation) should not exceed 25,000 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ocular infections:</b> Ophthalmic: A concentration of 0.1% to 0.25% is administered as 1 to 3 drops every hour, then increasing the interval as response indicates to 1 to 3 drops 4 to 6 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Systemic infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 25,000 to 30,000 units/kg/day divided every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 15,000 to 25,000 units/kg/day divided every 12 hours; <b>Note: </b>Safety data for single doses &gt;30,000 units/kg/dose or for daily doses &gt;2,000,000 units<b>/day </b>are extremely limited (Kassamali 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intrathecal: 50,000 units daily for 3 to 4 days, then every other day for at least 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Topical irrigation or topical solution:</b> 500,000 units/L of normal saline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: Note:</b> Some adult data suggest that renal adjustment may not be necessary since total body clearance of polymyxin B is not altered in the setting of renal impairment and nonrenal pathways are primarily responsible for elimination (Sandri 2013; Zavascki 2008). These authors suggest that renal dosage adjustment recommendations should await further data from larger clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Infants, Children, Adolescents, and Adults: For individuals with renal impairment, the manufacturer's labeling recommends a dosage reduction so that the dose does not exceed 15,000 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: Infants, Children, Adolescents, and Adults: The following adjustments have been used by some clinicians (modified from Hoeprich 1970): IV, IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose (first day of therapy): CrCl &lt;80 mL/minute: 25,000 units/kg in 2 equally divided doses every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Subsequent dosage:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 80 mL/minute: 10,000 to 15,000 units/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: 10,000 to 15,000 units/kg every 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Anuric patients: 10,000 units/kg every 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Adult: IM: 250,000 units every 24 hours; no supplemental dose necessary (Cunha 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Adult: IM: 250,000 units every 24 hours; no supplemental dose necessary (Cunha 1988)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211287\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211272\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049464\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Due to increased toxicity risks, the systemic use of polymyxin B should be avoided when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Not recommended for routine use in infants and children because of the severe pain associated with injection; should only be administered to hospitalized patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Infuse drug slowly, most data reports over 60 to 120 minutes (Teng 2008; Zavascki 2008) or by continuous infusion (per manufacturer's labeling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: May be administered intrathecally; only administer intrathecally to hospitalized patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: May be administered as a subconjunctival injection or as topical ophthalmic drops</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211302\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) and protect from light. After reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Discard any unused solution after 72 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049463\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> Parenteral use of polymyxin B has mainly been replaced by less toxic antibiotics. Due to increased toxicity risks, systemic use of polymyxin B should be limited to life-threatening, multidrug-resistant infections where less toxic alternatives are not effective or not tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: Treatment of acute systemic infections (excluding meningitis) caused by susceptible strains of <i>Pseudomonas aeruginosa</i> (FDA approved in all ages); treatment of serious acute infection caused by other susceptible gram negative organisms when other less potentially toxic agents are ineffective or contraindicated (FDA approved in all ages); solution for injection has also been used topically for wound irrigation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: Treatment of meningeal infection caused by susceptible strains of <i>Pseudomonas aeruginosa</i> or <i>Haemophilus influenza</i> (FDA approved in infants, children, adolescents, and adults); has also been administered intraventricularly for the treatment of CSF shunt infection/ventriculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Ophthalmic (topical or subconjunctival injection): Treatment of acute ophthalmic infections caused by susceptible strains of <i>Pseudomonas aeruginosa</i> (FDA approved in all ages); treatment of serious acute infection caused by other susceptible gram negative organisms when other less potentially toxic agents are ineffective or contraindicated (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5977966\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211332\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Facial flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Neurotoxicity (includes ataxia, blurred vision, drowsiness, irritability, numbness of extremities oral paresthesia), dizziness, drug fever, meningitis (intrathecal administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypocalcemia, hypochloremia, hypokalemia, hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Neuromuscular blockade, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211293\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polymyxin B or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211276\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local reactions: May cause severe pain at IM injection site or thrombophlebitis at IV infusion site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: May cause nephrotoxicity; avoid concurrent or sequential use of other nephrotoxic drugs.</b> Usual risk factors include preexisting renal impairment, advanced age and dehydration. Polymyxin B-induced nephrotoxicity may be manifested by albuminuria, cellular casts, and azotemia; monitor BUN, serum creatinine, and urinary analysis at baseline and as clinically indicated. Discontinue therapy with decreasing urinary output and increasing BUN. Data suggest polymyxin B undergoes a selective uptake process into renal cells, which plays a primary role in nephrotoxicity potential (Abdelraouf 2014). One small study in patients receiving polymyxin B with a normal baseline renal function observed an overall prevalence rate of nephrotoxicity of 46% with a median onset of 9 days (Dubrovaskaya 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity, which can also result in respiratory paralysis from neuromuscular blockade especially when the drug is given soon after anesthesia or muscle relaxants. Avoid concurrent or sequential use of other neurotoxic drugs.</b> Avoid concurrent use of curariform muscle relaxants and other neurotoxic drugs (eg, ether, tubocurarine, succinylcholine, gallamine, decamethonium, sodium citrate), which may cause respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function; manufacturer&rsquo;s prescribing information states dosage reduction required, however, recent pharmacokinetic/pharmacodynamic and clinical studies suggest daily dose requirement is not affected by renal function (Sandri 2013a; Nelson 2015; Thamlikitkul 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Safety in pregnant women not established.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IM/Intrathecal/IV administration: <b>[US Boxed Warning]:  Intramuscular/intrathecal/intravenous administration only to hospitalized patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral administration: Polymyxin B sulfate is most toxic when given parenterally; avoid parenteral use whenever possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26067366\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">IM use is not routinely recommended in infants and children due to severe pain at injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299903\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211281\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12716&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211295\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Safety in pregnant women has not been established.</b> Animal reproduction studies are lacking. A teratogenic potential has not been identified for polymyxin b, but very limited data is available (Heinonen 1977; Kazy 2005). Based on the relative toxicity compared to other antibiotics, systemic use in pregnancy is not recommended (Knothe 1985). Due to poor tissue diffusion, topical use would be expected to have only minimal risk to the mother or fetus (Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049459\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Neurologic symptoms and signs of superinfection; renal function (baseline and frequently during therapy; decreasing urine output and increasing BUN may require discontinuance of therapy); observe for changes in bowel frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211275\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to phospholipids, alters permeability, and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211292\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not absorbed from GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Tissue diffusion is poor; critically ill patients: Central V<sub>d</sub>: ~0.09 L/kg; peripheral V<sub>d</sub>: 0.33 L/kg (Sandri 2013a); does not cross blood brain barrier into CSF or into the eye (Hoeprich 1970)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~60% (Kassamali 2015); 79% to 92% (critically ill patients) (Zavascki 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6 hours, increased with reduced renal function (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: Within 2 hours (Hoeprich 1970)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;1% as unchanged drug within first 12 hours; as therapy continues, up to 60% as unchanged drug in the urine [Evans 1999]); Critically ill adults: Urine (median: 4% [range: 0.98% to 17.4%] as unchanged drug) (Sandri 2013a)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323703\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Polymyxin B Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500000 unit (1): $6.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539915\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerosporin (IN);</li>\n      <li>Alosol (MX);</li>\n      <li>Biodexan Ofteno (MX);</li>\n      <li>Cortisporin Otico (MX);</li>\n      <li>Dexsul (MX);</li>\n      <li>Glubacida (MX);</li>\n      <li>Isopto-Biotic (SE);</li>\n      <li>Maxitrol (MX);</li>\n      <li>Neobacigrin (MX);</li>\n      <li>Neosporin (MX);</li>\n      <li>Polixin (MX);</li>\n      <li>Poly-MXB (PH);</li>\n      <li>Polymyxin B Pfizer (DE);</li>\n      <li>Polymyxine B FNA (NL);</li>\n      <li>Septilisin (MX);</li>\n      <li>Synalar (MX);</li>\n      <li>Syntex (MX);</li>\n      <li>Tribiot (MX);</li>\n      <li>Trioft&iacute;n (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cunha BA, Friedman PE. Antibiotic dosing in patients with renal insufficiency or receiving dialysis. <i>Heart Lung</i>. 1988;17(6 Pt 1):612-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/3056882/pubmed\" target=\"_blank\" id=\"3056882\">3056882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. <i>Ann Pharmacother</i>. 1999 ;33(9):960-967.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/10492501/pubmed\" target=\"_blank\" id=\"10492501\">10492501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, &quot;Birth Defects and Drugs in Pregnancy,&quot; Publishing Sciences Group, Inc, Littleton, MA, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoeprich PD. The polymyxins. <i>Med Clin North Am</i>. 1970;54(5):1257-1265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/4319624/pubmed\" target=\"_blank\" id=\"4319624\">4319624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant <i>Acinetobacter</i> infections: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/5461655/pubmed\" target=\"_blank\" id=\"5461655\">5461655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazy Z, Puh&oacute; E, and Czeizel AE, &quot;Parenteral Polymyxin B Treatment During Pregnancy,&quot; <i>Reprod Toxicol</i>, 2005, 20(2):181-2<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/15907651/pubmed\" target=\"_blank\" id=\"15907651\">15907651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knothe H and Dette GA, &quot;Antibiotics in Pregnancy: Toxicity and Teratogenicity,&quot; <i>Infection</i>, 1985, 13(2):49-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/2987132/pubmed\" target=\"_blank\" id=\"2987132\">2987132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polymyxin B [prescribing information]. Big Flats, NY: X-GEN Pharmaceuticals; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polymyxin B [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polymyxin B [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. <i>Clin Infect Dis</i>. 2013;57(4):524-531.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/23697744/pubmed\" target=\"_blank\" id=\"23697744\">23697744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria.<i> Int J Antimicrob Agents</i>. 2008;31(1):80-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/17920246/pubmed\" target=\"_blank\" id=\"17920246\">17920246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. <i>Clin Infect Dis</i>. 2008;47(10):1298-1304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-pediatric-drug-information/abstract-text/18840079/pubmed\" target=\"_blank\" id=\"18840079\">18840079</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12716 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709216\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049460\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F25747919\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049454\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211287\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F211272\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049464\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F211302\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049463\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5977966\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211332\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211293\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211276\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26067366\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299903\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211281\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211295\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049459\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211275\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F211292\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323703\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539915\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12716|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">Polymyxin B: Drug information</a></li><li><a href=\"topic.htm?path=polymyxin-b-patient-drug-information\" class=\"drug drug_patient\">Polymyxin B: Patient drug information</a></li></ul></div></div>","javascript":null}